Physician profile
Alan Eric Bakst
NPI 1275580185
$3,559.45
in general payments reported to CMS, 2019-2025
25 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $255 · 2021: $359 · 2022: $384 · 2023: $542 · 2024: $606 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.63 |
| Education | $266.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $914.00 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $831.40 | 2021-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $174.98 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $173.99 | 2024-2025 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $164.83 | 2023-2025 | Terlivaz, Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.50 | 2020-2022 | |
| United Therapeutics Corporation | $137.43 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $124.46 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $121.01 | 2023-2024 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $109.20 | 2023-2025 | Glassia |
| Jazz Pharmaceuticals INC. | $104.04 | 2023-2024 | |
| Inogen, INC. | $89.73 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Harmony Biosciences LLC | $80.70 | 2023 | Wakix |
| Grifols USA, LLC | $59.89 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $51.93 | 2022-2024 | Fasenra, Breztri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.95 | 2019 | |
| Amgen INC. | $36.63 | 2024-2025 | Tezspire |
| Vifor Pharma, INC. | $33.75 | 2024 | Zemaira |
| Mylan Specialty L.P. | $30.41 | 2023-2024 | Yupelri |
| Ambu INC. | $30.32 | 2024 | |
| Resmed Corp | $29.96 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $29.54 | 2019 | |
| Genzyme Corporation | $19.95 | 2022 | |
| Apria Healthcare LLC | $17.27 | 2021 | |
| Electromed, INC. | $15.58 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bakst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.